ahlam1399
08-12-2016, 03:00 PM
BRIEF-Cynapsus Therapeutics an**unces publication in journal Movement Disorders of data for treatment of OFF episodes in patients with parkinson?s disease
* APL-130277 was safe and generally well-tolerated with **discontinuations because of adverse eventshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4_BUPqKMvso:KZ9EkUU8csM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4_BUPqKMvso:KZ9EkUU8csM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/4_BUPqKMvso
* APL-130277 was safe and generally well-tolerated with **discontinuations because of adverse eventshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4_BUPqKMvso:KZ9EkUU8csM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=4_BUPqKMvso:KZ9EkUU8csM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=4_BUPqKMvso:KZ9EkUU8csM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/4_BUPqKMvso